Abstract
Autoimmune hepatitis is characterized by a progressive destruction of the liver parenchyma and a chronic fibrosis. Although the major targets of this autoimmune-mediated disease have been identified more than two decades ago, the current treatment of autoimmune hepatitis is still based on traditional therapies including a glucocorticoid treatment. One reason for this impasse is the limited availability of reliable animal models that reflect the clinical features of autoimmune hepatitis and allow for the identification of critical factors driving the autoimmune destruction and the evaluation of innovative therapies. However, the status of the liver as an immune privileged organ harbouring many immunosuppressing mechanisms hampers the development of such models. Here we will review the past and present attempts to develop a consistent animal model for autoimmune hepatitis.
Keywords: Animal model, CYP2D6, immunotherapy, molecular mimicry, virus infection autoantibodies, liver fibrosis.
Current Pharmaceutical Design
Title:An Update on Animal Models of Autoimmune Hepatitis: Are we There Yet?
Volume: 21 Issue: 18
Author(s): Urs Christen and Edith Hintermann
Affiliation:
Keywords: Animal model, CYP2D6, immunotherapy, molecular mimicry, virus infection autoantibodies, liver fibrosis.
Abstract: Autoimmune hepatitis is characterized by a progressive destruction of the liver parenchyma and a chronic fibrosis. Although the major targets of this autoimmune-mediated disease have been identified more than two decades ago, the current treatment of autoimmune hepatitis is still based on traditional therapies including a glucocorticoid treatment. One reason for this impasse is the limited availability of reliable animal models that reflect the clinical features of autoimmune hepatitis and allow for the identification of critical factors driving the autoimmune destruction and the evaluation of innovative therapies. However, the status of the liver as an immune privileged organ harbouring many immunosuppressing mechanisms hampers the development of such models. Here we will review the past and present attempts to develop a consistent animal model for autoimmune hepatitis.
Export Options
About this article
Cite this article as:
Christen Urs and Hintermann Edith, An Update on Animal Models of Autoimmune Hepatitis: Are we There Yet?, Current Pharmaceutical Design 2015; 21 (18) . https://dx.doi.org/10.2174/1381612821666150316121319
DOI https://dx.doi.org/10.2174/1381612821666150316121319 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Are Circulating Monocytes as Microglia Orthologues Appropriate Biomarker Targets for Neuronal Diseases? (Supplementry Table)
Central Nervous System Agents in Medicinal Chemistry TCR Peptide Vaccination in Multiple Sclerosis: Boosting a Deficient Natural Regulatory Network that may Involve TCR-Specific CD4+CD25+ Treg Cells
Current Drug Targets - Inflammation & Allergy Pharmacological Tools to Activate Microglia and their Possible use to Study Neural Network Patho-physiology
Current Neuropharmacology Animal Models in Neurology: Drawbacks and Opportunities
Current Pharmaceutical Design CT and MR Imaging of the Encephalopathic Child
Current Medical Imaging Editorial (Thematic Issue: GABAergic Modulation as Treatment Strategy: Consideration of Several Diseases)
Current Pharmaceutical Design The Dopaminergic System in Peripheral Blood Lymphocytes: From Physiology to Pharmacology and Potential Applications to Neuropsychiatric Disorders
Current Neuropharmacology Ion Channels on Microglia: Therapeutic Targets for Neuroprotection
CNS & Neurological Disorders - Drug Targets Hemichannels in the Neurovascular Unit and White Matter Under Normal and Inflamed Conditions
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Neuroglia as a Central Element of Neurological Diseases: An Underappreciated Target for Therapeutic Intervention)
Current Neuropharmacology Inflammation and Inflammatory Cell Recruitment in Acute Cerebrovascular Diseases
Current Immunology Reviews (Discontinued) Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases
Current Neuropharmacology The Expanding Role of TNF-Receptor Super Family Member CD40 (tnfrsf5) in Autoimmune Disease: Focus on Th40 Cells
Current Immunology Reviews (Discontinued) Non-IgE Mediated Food Allergy – Update of Recent Progress in Mucosal Immunity
Inflammation & Allergy - Drug Targets (Discontinued) Managing Neuropathic Pain in Multiple Sclerosis: Pharmacological Interventions
Medicinal Chemistry MIP-1α and MCP-1 Induce Migration of Human Umbilical Cord Blood Cells in Models of Stroke
Current Neurovascular Research Neurodegeneration and Neuroprotection in Multiple Sclerosis
Current Pharmaceutical Design Vitamin D and Cystic Fibrosis Lung Disease
Mini-Reviews in Medicinal Chemistry Immunologic Modulations to Enhance Post-Stroke Recovery
Current Immunology Reviews (Discontinued) Calpain Inhibition: A Therapeutic Strategy Targeting Multiple Disease States
Current Pharmaceutical Design